Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy
The Journal of Pathology · 2024
DOI: 10.1002/path.6230 ↗At a glance
Journal article in The Journal of Pathology, 2024. Written by M Herman Chui and 9 co-authors. Institution: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Major MEDLINE topics: Erb-b2 Receptor Tyrosine Kinases, Endometrial Neoplasms. Cited 14 times so far (Crossref); 20 references. The full text is freely available in PubMed Central. Funded by: NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (original language)
Trastuzumab has demonstrated clinical efficacy in the treatment of HER2‐positive serous endometrial cancer (EC), which led to its incorporation into standard‐of‐care management of this aggressive disease. Acquired resistance remains an important challenge, however, and its underlying mechanisms in EC are unknown. To define the molecular changes that occur in response to anti‐HER2 therapy in EC, targeted next‐generation sequencing (NGS), HER2 immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) were performed on pre‐ and post‐treatment tumour samples from 14 patients with EC treated with trastuzumab or trastuzumab emtansine. Recurrent tumours after anti‐HER2 therapy acquired additional genetic alterations compared with matched pre‐treatment ECs and frequently showed decreased HER2 protein expression by IHC (7/14, 50%). Complete/near‐complete absence of HER2 protein expression (score 0/1+) observed post‐treatment (4/14, 29%) was associated with retained HER2 gene amplification ( n = 3) or copy number neutral status ( n = 1). Whole‐exome sequencing performed on primary and recurrent tumours from the latter case, which exhibited genetic heterogeneity of HER2 amplification in the primary tumour, revealed selection of an early HER2 ‐non‐amplified clone following therapy. Our findings demonstrate that loss of target expression, by selection of HER2 ‐non‐amplified clones or, more commonly, by downregulation of expression, may constitute a mechanism of resistance to anti‐HER2 therapy in HER2‐positive EC. © 2023 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID profiles: M Herman Chui, Jorge S Reis-Filho, Britta Weigelt
Funding
- NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- National Cancer Institute
- Breast Cancer Research Foundation
- National Institutes of Health
Cite
APA
Chui, M. H., Brown, D. N., Da Cruz Paula, A., da Silva, E. M., Momeni-Boroujeni, A., Reis-Filho, J. S., Zhang, Y., Makker, V., Ellenson, L. H., & Weigelt, B. (2024). Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy. The Journal of Pathology. https://doi.org/10.1002/path.6230
Vancouver
Chui MH, Brown DN, Da Cruz Paula A, da Silva EM, Momeni-Boroujeni A, Reis-Filho JS, et al. Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy. The Journal of Pathology. 2024. doi:10.1002/path.6230
BibTeX
@article{Chui2024,
author = {Chui, M Herman and Brown, David N and Da Cruz Paula, Arnaud and da Silva, Edaise M and Momeni-Boroujeni, Amir and Reis-Filho, Jorge S and Zhang, Yanming and Makker, Vicky and Ellenson, Lora Hedrick and Weigelt, Britta},
title = {Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy},
journal = {The Journal of Pathology},
year = {2024},
doi = {10.1002/path.6230}
}
EUVIMED